Skip to main content

Table 2 Final population parameter estimates of LPV with their bootstrap evaluations

From: Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study

Parameters

Final model

Bootstrap (n = 2000 samples)

Estimate

RSE (%)a

BSV (%)b

RSE (%)a

Median

CI95%c

BSV (%)b

CI95%c

ka (h−1)

0.76

3

  

0.75

0.37—66.41*

  

VLPV (L)

78.9

2

  

77.7

52.2—119.5

  

CLLPV (L/h)

4.02

3

28.5

14

4.00

3.71—4.32

28.0

18.8—35.9

θBW

0.447

14

  

0.447

0.196—0.733

  

σprop (%)

33.3

11

  

32.7

23.0—39.6

  

σadd (ng/mL)

1560

1

  

1544

1005—2247

  
  1. Final model:
  2. \({TVCL}_{LPV} = {CL}_{LPV}*\left(1+ {\theta }_{BW}*\frac{BW-70}{70}\right)\)
  3. ka first-order absorption rate constant, VLPV apparent volume of distribution of lopinavir, CLLPV apparent clearance of lopinavir, θBW bodyweight effect on CLLPV with reference bodyweight of 70 kg, σprop proportional residual error; σadd: additive residual error
  4. aRelative standard error (RSE) of the estimate defined as SE estimate/estimate, expressed as a percentage, with SE estimate retrieved directly from the NONMEM output file
  5. bBetween-subject variability
  6. c95% confidence interval
  7. *See Figure S2 for illustration of the CI95% estimated for ka after bootstrapping
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us